Federal Research Institute of Pediatric Hematology, Oncology and Immunology

๐Ÿ‡ท๐Ÿ‡บRussia
Ownership
Private
Employees
-
Market Cap
-
Website

Cognitive and Motor Training in Pediatric Posterior Fossa Tumor Survivors

First Posted Date
2019-05-15
Last Posted Date
2019-05-23
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
60
Registration Number
NCT03951246
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology, Moscow, Russian Federation

Modification of the Human Colon and Oral Microbiome by Allogenic HSCT

First Posted Date
2019-05-08
Last Posted Date
2020-04-07
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
15
Registration Number
NCT03942159
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

First Posted Date
2019-03-14
Last Posted Date
2019-03-14
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
25
Registration Number
NCT03874273
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2019-02-19
Last Posted Date
2023-03-16
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
500
Registration Number
NCT03846362
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

๐Ÿ‡ท๐Ÿ‡บ

Regional Children's Clinical Hospital โ„– 1, Ekaterinburg, Sverdlovsk Oblast, Russian Federation

Metabolic Syndrome in Childhood Cancer Survivors

First Posted Date
2018-12-12
Last Posted Date
2018-12-20
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
400
Registration Number
NCT03773718
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

First Posted Date
2018-11-02
Last Posted Date
2018-11-02
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
62
Registration Number
NCT03728543
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

First Posted Date
2018-07-13
Last Posted Date
2023-03-16
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
12
Registration Number
NCT03585686
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Creating a Decision Support System for the Corporate Management of Physical Therapy

First Posted Date
2018-07-13
Last Posted Date
2018-07-13
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
1000
Registration Number
NCT03586401
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology, Moscow, Russian Federation

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

First Posted Date
2018-06-06
Last Posted Date
2019-09-17
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
17
Registration Number
NCT03547830
Locations
๐Ÿ‡ท๐Ÿ‡บ

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)

Phase 2
Conditions
Interventions
First Posted Date
2018-03-22
Last Posted Date
2020-07-21
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
80
Registration Number
NCT03474133
Locations
๐Ÿ‡ท๐Ÿ‡บ

City clinical hospital โ„–40, Moscow, Russian Federation

๐Ÿ‡ท๐Ÿ‡บ

R. Gorbacheva Research Institute of Pediatric Hematology and Transfusiology; Pavlov State Medical University of Saint-Petersburg, Saint Petersburg, Russian Federation

ยฉ Copyright 2024. All Rights Reserved by MedPath